Immunotherapy Study for Surgically Resected Pancreatic Cancer

This study is currently recruiting participants.

Verified May 2013 by NewLink Genetics Corporation

Sponsor:

Information provided by (Responsible Party):

NewLink Genetics Corporation

ClinicalTrials.gov Identifier:

NCT01072981

First received: February 18, 2010

Last updated: May 21, 2013

Last verified: May 2013

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study is currently recruiting participants.
Estimated Study Completion Date:	January 2014
Estimated Primary Completion Date:	January 2014 (Final data collection date for primary outcome measure)

No publications provided by NewLink Genetics Corporation

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Hardacre JM, Mulcahy M, Small W, Talamonti M, Obel J, Krishnamurthi S, Rocha-Lima CS, Safran H, Lenz HJ, Chiorean EG. Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study. J Gastrointest Surg. 2013 Jan;17(1):94-100; discussion p. 100-1. doi: 10.1007/s11605-012-2064-6. Epub 2012 Nov 15.

To Top